logo
This isn't a galaxy — it's a map of a mouse's brain

This isn't a galaxy — it's a map of a mouse's brain

CBC10-04-2025

Thanks to a mouse watching clips from The Matrix, scientists have created the largest functional map of a brain to date — a diagram of the wiring connecting 84,000 neurons as they fire off messages.
Using a piece of that mouse's brain about the size of a poppyseed, the researchers identified those neurons and traced how they communicated via branch-like fibres through a surprising 500 million junctions called synapses.
The massive dataset, published Wednesday by the journal Nature, marks a step toward unravelling the mystery of how our brains work. The data, assembled in a 3D reconstruction, coloured to delineate different brain circuitry, is open to scientists worldwide for additional research — and for the simply curious to take a peek.
"It definitely inspires a sense of awe, just like looking at pictures of the galaxies," said Forrest Collman, of the Allen Institute for Brain Science in Seattle, one of the project's leading researchers.
"You get a sense of how complicated you are. We're looking at one tiny part … of a mouse's brain, and the beauty and complexity that you can see in these actual neurons and the hundreds of millions of connections between them."
How we think, feel, see, talk and move are due to neurons, or nerve cells, in the brain: how they're activated and send messages to each other. Scientists have long known those signals move from one neuron along fibres called axons and dendrites, using synapses to jump to the next neuron. But there's less known about the networks of neurons that perform certain tasks and how disruptions of that wiring could play a role in Alzheimer's, autism or other disorders.
"You can make a thousand hypotheses about how brain cells might do their job, but you can't test those hypotheses unless you know perhaps the most fundamental thing — how are those cells wired together," said Allen Institute scientist Clay Reid, who helped pioneer electron microscopy to study neural connections.
Uncrossing the wires
With the new project, a global team of more than 150 researchers mapped neural connections that Collman compares to tangled pieces of spaghetti winding through part of the mouse brain responsible for vision.
The first step: Show a mouse video snippets of sci-fi movies, sports, animation and nature.
A team at Baylor College of Medicine did just that, using a mouse engineered with a gene that makes its neurons glow when they're active. The researchers used a laser-powered microscope to record how individual cells in the animal's visual cortex lit up as they processed the images flashing by.
WATCH | Allen Institute video reveals largest wiring diagram and functional map of the brain:
Next, scientists at the Allen Institute analyzed that small piece of brain tissue, using a special tool to shave it into more than 25,000 layers, each far thinner than a human hair. With electron microscopes, they took nearly 100 million high-resolution images of those sections, illuminating those spaghetti-like fibres and painstakingly reassembling the data in 3D.
Finally, Princeton University scientists used artificial intelligence to trace all that wiring and to "paint each of the individual wires a different colour so that we can identify them individually," Collman explained.
They estimated that microscopic wiring, if laid out, would measure more than five kilometres. Importantly, matching up all that anatomy with the activity in the mouse's brain as it watched movies allowed researchers to trace how the circuitry worked.
WATCH | MICrONS consortium video explores the connections of the brain:
The Princeton researchers also created digital 3D copies of the data that other scientists can use in developing new studies.
Could this kind of mapping help scientists eventually find treatments for brain diseases? The researchers call it a foundational step, like how the Human Genome Project that provided the first gene-mapping eventually led to gene-based treatments. Mapping a full mouse brain is one next goal.
"The technologies developed by this project will give us our first chance to really identify some kind of abnormal pattern of connectivity that gives rise to a disorder," another of the project's leading researchers, Princeton neuroscientist and computer scientist Sebastian Seung, said in a statement.
The work "marks a major leap forward and offers an invaluable community resource for future discoveries," wrote Harvard neuroscientists Mariela Petkova and Gregor Schuhknecht, who weren't involved in the project.
The huge and publicly shared data "will help to unravel the complex neural networks underlying cognition and behaviour," they added.
The Machine Intelligence from Cortical Networks, or MICrONS, consortium was funded by the U.S. National Institutes of Health's BRAIN Initiative and IARPA, the Intelligence Advanced Research Projects Activity.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Xanadu Unveils First On-Chip Error-Resistant Photonic Qubit
Xanadu Unveils First On-Chip Error-Resistant Photonic Qubit

Cision Canada

timea day ago

  • Cision Canada

Xanadu Unveils First On-Chip Error-Resistant Photonic Qubit

TORONTO, June 4, 2025 /CNW/ - Xanadu has achieved a significant milestone in the development of scalable quantum hardware by generating error-resistant photonic qubits on an integrated chip platform. A foundational result in Xanadu's roadmap, this first-ever demonstration of such qubits on a chip is now published in Nature. This breakthrough builds on Xanadu's recent announcement of the Aurora system, which demonstrated—for the first time—all key components required to build a modular, networked, and scalable photonic quantum computer. With this latest demonstration of robust qubit generation using silicon-based photonic chips, Xanadu further strengthens the scalability pillar of its architecture. The quantum states produced in this experiment, known as GKP states, consist of superpositions of many photons to encode information in an error-resistant manner—an essential requirement for future fault-tolerant quantum computers. These states allow logic operations to be performed using deterministic, room-temperature-compatible techniques, and they are uniquely well-suited for networking across chips using standard fiber connections. This demonstration of generating photonic qubits was enabled by a number of key technological achievements from Xanadu's hardware team. These include the development of photon-number-resolving detectors with detection efficiencies above 99%, the fabrication of customized ultra-low loss silicon nitride waveguides on 300 mm wafer platforms, and the implementation of in-house state-of-the-art optical packaging. "GKP states are, in a sense, the optimal photonic qubit, since they enable logic gates and error correction at room temperature and using relatively straightforward, deterministic operations," says Zachary Vernon, CTO of Hardware at Xanadu. "This demonstration is an important empirical milestone showing our recent successes in loss reduction and performance improvement across chip fabrication, component design, and detector efficiency." The next hurdle towards a utility-scale photonic quantum computer remains clear: further reduction of optical loss will allow for higher quality GKP states suitable for fault-tolerance. With another significant milestone in its hardware roadmap complete, Xanadu remains focused on further optimizing fabrication and photonics packaging processes to alleviate optical loss across its platform. About Xanadu: Xanadu is a Canadian quantum computing company with the mission to build quantum computers that are useful and available to people everywhere. Founded in 2016, Xanadu has become one of the world's leading quantum hardware and software companies. The company also leads the development of PennyLane, an open-source software library for quantum computing and application development. Visit or follow us on X @XanaduAI.

Astronomers discover strange new celestial object in our Milky Way galaxy
Astronomers discover strange new celestial object in our Milky Way galaxy

Winnipeg Free Press

time28-05-2025

  • Winnipeg Free Press

Astronomers discover strange new celestial object in our Milky Way galaxy

CAPE CANAVERAL, Fla. (AP) — Astronomers have discovered a strange new object in our Milky Way galaxy. An international team reported Wednesday that this celestial object — perhaps a star, pair of stars or something else entirely — is emitting X-rays around the same time it's shooting out radio waves. What's more, the cycle repeats every 44 minutes, at least during periods of extreme activity. Located 15,000 light-years away in a region of the Milky Way brimming with stars, gas and dust, this object could be a highly magnetized dead star like a neutron or white dwarf, Curtin University's Ziteng Andy Wang said in an email from Australia. Or it could be 'something exotic' and unknown, said Wang, lead author of the study published in the journal Nature. NASA's Chandra X-ray Observatory spotted the X-ray emissions by chance last year while focusing on a supernova remnant, or the remains of an exploded star. Wang said it was the first time X-rays had been seen coming from a so-called long-period radio transient, a rare object that cycles through radio signals over tens of minutes. Given the uncertain distance, astronomers can't tell if the weird object is associated with the supernova remnant or not. A single light-year is 5.8 trillion miles. The hyperactive phase of this object — designated ASKAP J1832−091 — appeared to last about a month. Outside of that period, the star did not emit any noticeable X-rays. That could mean more of these objects may be out there, scientists said. 'While our discovery doesn't yet solve the mystery of what these objects are and may even deepen it, studying them brings us closer to two possibilities,' Wang said. 'Either we are uncovering something entirely new, or we're seeing a known type of object emitting radio and X-ray waves in a way we've never observed before.' Launched in 1999, Chandra orbits tens of thousands of miles (kilometers) above Earth, observing some of the hottest, high-energy objects in the universe. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.

Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award
Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award

National Post

time27-05-2025

  • National Post

Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award

Article content Article content OSAKA, Japan & CAMBRIDGE, Mass. — Takeda (TSE:4502/NYSE:TAK) today announced that applications are now open for its Innovators in Science Award. This prestigious global award, originally launched in 2016, celebrates groundbreaking research with a focus on emerging scientific leaders who are advancing the frontiers of scientific discovery and fostering innovation that has the potential to transform lives. Article content In 2026, the Takeda Innovators in Science Award with Nature will recognize promising early-career scientists in the areas of gastrointestinal and inflammatory diseases, neuroscience, and oncology. Takeda will award three category winners – one from each area of focus – with a $75,000 prize. One grand prize winner, to be announced live at the Innovators in Science Award gala on April 9, 2026, will also receive an additional $175,000 award, for a total grand prize of $250,000. Article content To address challenges that are unique to emerging scientists, category winners and shortlisted applicants will be invited to participate in a 12-month career development program administered by Nature. The program will offer training to develop skills such as grant writing, research communication and lab management. Winners will also have access to mentorship opportunities. Article content As one of the largest prizes of its kind, the Innovators in Science Award reinforces Takeda's commitment to promoting scientific excellence and fostering a culture of partnership between industry and academia. Article content 'Since 2016, our Innovators in Science Award has uplifted researchers who are not afraid of asking big questions, thinking outside the box and doggedly pursuing discoveries to advance science,' said Andrew Plump, M.D., Ph.D., president of R&D at Takeda. 'We are proud to shine a spotlight on rising scientists who are driving bold, transformative breakthroughs in their fields. Through funding, mentorship, and collaboration opportunities, we aim to support their continued professional growth.' Article content Springer Nature will independently administer the award on behalf of Takeda, with responsibility for reviewing applications and selecting judges and winners. Article content 'For 150 years, Nature has earned the trust of the global research community by publishing groundbreaking advances across all areas of science and technology. We recognize the vital contributions of early-career researchers and are committed to supporting their growth and success,' added Nature's publisher Richard Hughes. 'We are proud to partner with Takeda on the Innovators in Science Award—an initiative designed to celebrate and elevate the work of exceptional early-career scientists. We invite researchers around the world to apply, and we remain dedicated to providing a rigorous evaluation process and amplifying the voices and achievements of the award winners across our platforms.' Article content The Call for Applications is now open at and will remain open through September 16, 2025. Shortlisted applicants will be announced in January 2026 and category winners will be announced in February 2026, ahead of the live grand prize announcement at the gala on April 9, 2026, in Boston. Article content About the Innovators in Science Award Launched in 2016, the Takeda Innovators in Science Award provides scientific leaders with the support and recognition needed to drive bold, transformative breakthroughs in their fields. Since its inception, the award has celebrated the outstanding contributions of 10 established and early career researchers with $2M of unrestricted funding. This global award recognizes researchers who are advancing the frontiers of scientific discovery, fostering innovation that has the potential to transform lives. In 2026, the Innovators in Science Award honors groundbreaking research by early career scientists in gastrointestinal and inflammatory diseases, neuroscience and oncology. Past winners include: Elham Azizi, Ph.D., for her innovative models that helped identify determinants of immunotherapy response in leukemia for the first time; Elaine Y. Hsiao, Ph.D., for her discoveries of how the gut microbiome influences the brain and behavior; and Viviana Gradinaru, Ph.D., for enabling targeted gene delivery across the blood-brain barrier for research and clinical purposes. For more information, visit Article content About Takeda Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit Article content Important Notice For the purposes of this notice, 'press release' means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ('Takeda') regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. Article content The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, 'Takeda' is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words 'we', 'us' and 'our' are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies. Article content Forward-Looking Statements This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as 'targets', 'plans', 'believes', 'hopes', 'continues', 'expects', 'aims', 'intends', 'ensures', 'will', 'may', 'should', 'would', 'could', 'anticipates', 'estimates', 'projects' or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda's global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda's operations and the timing of any such divestment(s); and other factors identified in Takeda's most recent Annual Report on Form 20-F and Takeda's other reports filed with the U.S. Securities and Exchange Commission, available on Takeda's website at: or at Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda's future results. Article content Article content Article content Article content Article content Contacts Article content Media Contacts: Article content Article content

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store